Simponi Insurance Denied? How to Appeal Your Golimumab Denial

Simponi and Simponi Aria (golimumab) are FDA-approved anti-TNF biologics for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis. Simponi is a monthly subcutaneous injection; Simponi Aria is an intravenous infusion. Despite their established clinical track record, insurance denials for golimumab are common. Here's how to build a successful appeal.

What Simponi Treats and Why Patients Need It

Golimumab is a human monoclonal antibody that binds to tumor necrosis factor alpha (TNF-α), blocking the inflammatory signaling at the heart of several immune-mediated diseases.

FDA-approved indications:

• Moderate-to-severe rheumatoid arthritis (in combination with methotrexate)
• Active ankylosing spondylitis
• Active psoriatic arthritis
• Moderate-to-severe ulcerative colitis (Simponi only, for patients who have failed conventional therapy)

For patients with inflammatory arthritis, Simponi prevents joint destruction that causes permanent disability. For ulcerative colitis patients who have failed or cannot tolerate aminosalicylates and corticosteroids, Simponi is an established biologic option that can induce and maintain remission.

Common Denial Reasons for Simponi

Step therapy requirements: For RA and spondyloarthritis, plans typically require failure of conventional DMARDs — primarily methotrexate for RA — before any biologic is approved. For UC, failure of 5-ASA and corticosteroids is usually required.

Preferred anti-TNF not tried: Most plans have formulary-preferred TNF inhibitors (typically Humira/adalimumab biosimilars or Enbrel/etanercept biosimilars) and require a failed trial of those agents before approving Simponi.

IV vs. subcutaneous formulation dispute: Plans may approve Simponi subcutaneous but deny Simponi Aria (IV formulation), or vice versa, even when the prescribing physician has a clinical reason for the specific formulation.

UC indication covered differently: Some plans cover Simponi under a GI formulary rather than the rheumatology formulary, and coverage criteria may differ between departments.

Disease severity not documented: Plans typically require moderate-to-severe disease documented with validated scores before approving biologic therapy.

Step-by-Step: How to Appeal a Simponi Denial

Step 1: Get the denial in writing and identify the exact reason. Formulary preference? Step therapy? Indication-specific coverage issue?

Step 2: Document your DMARD or conventional therapy history. For RA: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine trials. For UC: mesalamine, prednisone, azathioprine, 6-MP trials.

Step 3: Document disease activity scores. DAS28 or CDAI for RA, BASDAI/ASDAS for AS, BSA for PsA, Mayo score for UC.

Step 4: If denied in favor of a preferred TNF, document the reason for selecting golimumab. Prior failure or intolerance of the preferred agent, or a clinical reason for the specific formulation (e.g., IV preferred for patient unable to self-inject), should be noted in the LMN.

Step 5: Have your rheumatologist or gastroenterologist write a Letter of Medical Necessity. Include diagnosis, disease severity, prior treatments, and clinical rationale for Simponi.

Step 6: File the internal appeal and request peer-to-peer review.

Step 7: File an external appeal if needed.

What to Include in Your Simponi Appeal Letter

• Policy number, member ID, and claim reference
• Golimumab (Simponi or Simponi Aria) prescribed dose, route, and indication
• Disease activity documentation (DAS28, BASDAI, Mayo score, etc.)
• Prior conventional therapy history with dates, doses, and outcomes
• Prior biologic history if applicable
• Clinical reason for golimumab specifically over formulary-preferred alternatives
• Letter of Medical Necessity from rheumatologist or gastroenterologist
• FDA approval citations for the specific indication
• ACR, ECCO, EULAR, or AGA guideline citations
• Request for peer-to-peer review

Success Tips for Simponi Appeals

Document prior anti-TNF failure specifically. If Humira or Enbrel was tried and failed — due to lack of efficacy or adverse effects — this is the strongest basis for a Simponi exception. Be specific: drug name, dose, duration, and reason for failure.

Include the formulation rationale for Simponi Aria. If your physician prescribed Simponi Aria (IV) rather than the subcutaneous formulation, document why — perhaps the patient is needle-phobic, has injection site reactions, has compliance issues with self-injection, or the IV formulation provides more consistent pharmacokinetics for a specific clinical scenario.

Quantify your disease burden. High disease activity scores, functional limitations (HAQ score for RA), or prior hospitalizations for UC make a strong case that this is not a preference but a medical necessity.

Address the UC indication specifically. For ulcerative colitis, the treatment algorithm is different from RA. If you've failed aminosalicylates and corticosteroids, make this explicit and cite ECCO or AGA guidelines recommending biologic therapy for moderate-to-severe UC.

Fight Back With ClaimBack

Simponi has helped countless patients manage serious autoimmune diseases. If your insurer denied your claim, ClaimBack can help you build a clear, evidence-backed appeal to fight for the treatment your doctor prescribed.

Start your Simponi appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals